Fundz
Real-time · AI · Cross-signal

Exscientia just moved. Here's exactly what to do next.

Who to reach, what to say, and why now — on Exscientia, plus every contract, funding round, and exec hire that follows. Verified, ICP-ranked contacts on demand (email + mobile).

Used by professionals at BlackRock, Oracle, Kleiner Perkins, HubSpot, and other leading firms — built on 10 years of proprietary signal data.

Choose your planRequest a demo
▶
Watch the 2-minute tour · with sound

Recursion and Exscientia Enter Definitive Agreement to Combine Forces in Drug Discovery

Aug 08, 2024•almost 2 years ago

Contract Type

agreement

BiotechnologyHealth Care

Description

Recursion (Nasdaq: RXRX) and Exscientia plc (Nasdaq: EXAI) have entered into a definitive agreement to combine forces, aiming to industrialize drug discovery, deliver high-quality medicines, and lower prices for consumers. The agreement aims to bring together their respective expertise and capabilities in technology-enabled biology, chemistry exploration, precision oncology, rare disease, and infectious disease treatments.

Company Information

Company

Exscientia

About

Exscientia is an AI-driven pharmatech company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner. Exscientia developed the first-ever functional precision oncology platform to successfully guide treatment selection and improve patient outcomes in a prospective interventional clinical study, as well as to progress AI-designed small molecules into the clinical setting. Our pipeline demonstrates our ability to rapidly translate scientific concepts into precision-designed therapeutic candidates, with more than 25 projects advancing, including the first three AI-designed drug candidates to enter Phase 1 clinical trials.

Predictive Intelligence
Strategic

ML-powered predictions for Exscientia's next move

Learn about Strategic plan

Agreement Insights

Based on industry data
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months